How to acknowledge FP7 in publication ?
All publications shall include the following statement to indicate that
said foreground was generated with the assistance of financial support
from the Community (see Article II.30. of the Grant Agreement):
The research leading to these results has received funding from
the European Community's Seventh Framework Programme FP7/2007-2011
under grant agreement n°201279.
|
|
News
|
"MicroRNA and small non coding RNA: new actors in physiopathology" October 14-16, 2009 Nice - France
 |
During the last decade, the discovery and characterization of microRNAs (miRNAs)
have shed a new light on gene regulation. Combination of bioinformatics and
experimental analyses have shown that an important part of all existing mRNAs may
interact with miRNAs, which play a key role in many distinct cellular processes such as
viral infection, cell differentiation, proliferation, apoptosis or metabolism.
Several inflammatory, neurodegenerative or cardiac pathologies have been clearly
associated with miRNA dysregulation. MiRNAs have also been implicated in several
carcinogenesis processes where they can act as either tumor suppressors or
oncogenes. Many research teams are now working on the use of miRNA expression
signatures for diagnostic, or try to interfere with miRNA function for targeted
therapeutic purposes.
This meeting has been aimed at giving a state of art in many recent breakthroughs in
miRNA and pathologies both at a fundamental and at a clinical point of view.
http://www.groupebioldev.asso.fr
|
|
HEALTH-2007-2.4.1-6:
Understanding and fighting metastasis.
Micro-Environment and Metastasis
|
The MICROENVIMET project proposes innovative approaches for building a
comprehensive understanding of the interplay between
cancer cells and
their microenvironment both at primary and secondary sites.
The objectives are to identify molecular pathways involved in
the regulation of metastatic dissemination to lung, liver,
lymph node and bone. To achieve these objectives, the original
experimental approach proposed is to modulate the production/activity
of proteases or their inhibitors.
Proteases are now recognized as key
regulators of a complex network of interacting molecules that modulate
the properties of cancer cells and their microenvironment. The project
is intended to identify key molecular pathways underlying early steps
of metastatic dissemination by interfering with the protease network
and studying the impact of such experimentally manipulated microenvironment
on metastasis formation. In addition to identifying key regulators of
metastasis, we aim at developing blocking antibodies towards these new
candidates, with efficacy for therapeutic intervention, by using the most
advanced state-of-the-art technologies. The study of cancer stem cells
will be integrated into current concepts that consider and attempt to
explain the importance of the microenvironment during cancer progression.
The 9 academic participants will combine expertise in genomics, proteomics,
bioinformatics, in vivo imaging, transgenic mice, mouse models of metastasis,
genetic manipulation of transplantable tumor
cells, computerized image analysis,
virus-mediated gene transfer, phage display and production of neutralizing antibodies.
This consortium will facilitate shared access to a new microRNA platform, innovative
technologies, human tumor tissue banks, in vivo and in vitro models mimicking different
steps of metastatic dissemination, as well as know how in tumor-host cell interplay,
angiogenesis, lymphangiogenesis, cancer stem cell biology and generation of database.
|
|
Consortium members
|
Partner 1 : University of Ličge, LBTD, GIGA-Cancer, Belgium (Pr. A. Noel, Coordinator)
Partner 2 : University of Helsinki, Finland (Prof Kari Alitalo & Dr Pirjo Laakanen)
Partner 3 : University of Torino, Italy (Prof Paolo Comoglio et Prof Carla Boccaccio)
Partner 4 : Technical University of Munchen, Germany (Prof Achim Krüger)
Partner 5 : University of Oviedo, Spain (Prof Carlos López-Otín)
Partner 6 : CNRS - University of Sophia Antipolis, France (Prof Pascal Barbry & Dr Bernard Mari)
Partner 7 : Freiburg University Hospital, Germany (Prof Thomas Reinheckel)
Partner 8 : Finsen Laboratory, Danemark (Prof. Gunilla Hřyer-Hansen & Prof. Niels Behrendt)
Partner 9 : Jozef Stefan Institute, Slovenia (Prof Boris Turk & Dr Olga Vasiljeva)
|
|
Work Package description
|
WP1 Tumor cells and cancer stem cells in the context of metastasis
WP2 The microenvironment in primary tumor
WP3 The pre-metastatic niche
WP4 Anti-metastatic therapy in transgenic cancer models
WP5 Integration and management of microarray information
WP6 Dissemination of results for clinical implications
WP7 Project Management
|
|
